Literature DB >> 17219756

The application of a Bayesian approach to the analysis of a complex, mechanistically based model.

Fredrik Jonsson1, E Niclas Jonsson, Frédéric Y Bois, Scott Marshall.   

Abstract

The Bayesian approach has been suggested as a suitable method in the context of mechanistic pharmacokinetic-pharmacodynamic (PK-PD) modeling, as it allows for efficient use of both data and prior knowledge regarding the drug or disease state. However, to this day, published examples of its application to real PK-PD problems have been scarce. We present an example of a fully Bayesian re-analysis of a previously published mechanistic model describing the time course of circulating neutrophils in stroke patients and healthy individuals. While priors could be established for all population parameters in the model, not all variability terms were known with any degree of precision. A sensitivity analysis around the assigned priors used was performed by testing three different sets of prior values for the population variance terms for which no data were available in the literature: "informative", "semi-informative", and "noninformative", respectively. For all variability terms, inverse gamma distributions were used. It was possible to fit the model to the data using the "informative" priors. However, when the "semi-informative" and "noninformative" priors were used, it was impossible to accomplish convergence due to severe correlations between parameters. In addition, due to the complexity of the model, the process of defining priors and running the Markov chains was very time-consuming. We conclude that the present analysis represents a first example of the fully transparent application of Bayesian methods to a complex, mechanistic PK-PD problem with real data. The approach is time-consuming, but enables us to make use of all available information from data and scientific evidence. Thereby, it shows potential both for detection of data gaps and for more reliable predictions of various outcomes and "what if" scenarios.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17219756     DOI: 10.1080/10543400600851898

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  8 in total

1.  Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Authors:  Jakob Ribbing; Andrew C Hooker; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-11-08       Impact factor: 2.745

2.  Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.

Authors:  Nikolaos Tsamandouras; Gemma Dickinson; Yingying Guo; Stephen Hall; Amin Rostami-Hodjegan; Aleksandra Galetin; Leon Aarons
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

3.  Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.

Authors:  Markus Krauss; Kai Tappe; Andreas Schuppert; Lars Kuepfer; Linus Goerlitz
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

4.  Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.

Authors:  Thierry Wendling; Nikolaos Tsamandouras; Swati Dumitras; Etienne Pigeolet; Kayode Ogungbenro; Leon Aarons
Journal:  AAPS J       Date:  2015-11-04       Impact factor: 4.009

5.  Addressing human variability in next-generation human health risk assessments of environmental chemicals.

Authors:  Lauren Zeise; Frederic Y Bois; Weihsueh A Chiu; Dale Hattis; Ivan Rusyn; Kathryn Z Guyton
Journal:  Environ Health Perspect       Date:  2012-10-19       Impact factor: 9.031

6.  An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.

Authors:  James Lu; Katrin Hübner; M Nazeem Nanjee; Eliot A Brinton; Norman A Mazer
Journal:  PLoS Comput Biol       Date:  2014-03-13       Impact factor: 4.475

7.  A bayesian perspective on estimation of variability and uncertainty in mechanism-based models.

Authors:  T A Leil
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-25

8.  Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model.

Authors:  T A Leil; S Kasichayanula; D W Boulton; F LaCreta
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.